Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

Bhatia A, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Lacouture ME, Hajdenberg J, Ganzel C, Diamond EL.

Haematologica. 2018 Apr;103(4):e177-e180. doi: 10.3324/haematol.2017.185298. Epub 2018 Feb 22. No abstract available.

2.

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, Robles R, Flowers CR, Collins R, DiBella NJ, Papish SW, Venugopal P, Horodner A, Tabatabai A, Hajdenberg J, Park J, Neuwirth R, Mulligan G, Suryanarayan K, Esseltine DL, de Vos S.

J Clin Oncol. 2017 Nov 1;35(31):3538-3546. doi: 10.1200/JCO.2017.73.2784. Epub 2017 Sep 1.

PMID:
28862883
3.

Successful treatment of chronic recurrent life-threatening bleeding due to an acquired factor V Inhibitor with rituximab and steroids.

Patel MD, Hajdenberg J.

Haemophilia. 2016 May;22(3):e231-2. doi: 10.1111/hae.12915. Epub 2016 Mar 31. No abstract available.

PMID:
27029965
4.

ACP Journal Club. In high-risk patients, oral nicotinamide reduced number of new nonmelanoma skin cancers during treatment.

Hajdenberg J.

Ann Intern Med. 2016 Feb 16;164(4):JC18. doi: 10.7326/ACPJC-2016-164-4-018. No abstract available.

PMID:
26882303
5.

Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.

Faltas B, Goldenberg DM, Ocean AJ, Govindan SV, Wilhelm F, Sharkey RM, Hajdenberg J, Hodes G, Nanus DM, Tagawa ST.

Clin Genitourin Cancer. 2016 Feb;14(1):e75-9. doi: 10.1016/j.clgc.2015.10.002. Epub 2015 Oct 19.

6.

Refractory Epistaxis due to Severe Factor V Deficiency with Inhibitor.

John ES, Patel MD, Hajdenberg J.

Case Rep Hematol. 2015;2015:603402. doi: 10.1155/2015/603402. Epub 2015 Aug 9.

7.

Severe dermatologic reactions with bendamustine: a case series.

Carilli A, Favis G, Sundharkrishnan L, Hajdenberg J.

Case Rep Oncol. 2014 Jul 12;7(2):465-70. doi: 10.1159/000365324. eCollection 2014 May.

8.

ACP Journal Club. Radical prostatectomy reduced long-term mortality more than watchful waiting in early prostate cancer.

Hajdenberg J.

Ann Intern Med. 2014 Jun 17;160(12):JC10. doi: 10.7326/0003-4819-160-12-201406170-02010. No abstract available.

PMID:
24935504
9.

Pheochromocytoma of the urinary bladder: a systematic review of the contemporary literature.

Beilan JA, Lawton A, Hajdenberg J, Rosser CJ.

BMC Urol. 2013 Apr 29;13:22. doi: 10.1186/1471-2490-13-22. Review.

10.

Locally advanced paraganglioma of the urinary bladder: a case report.

Beilan J, Lawton A, Hajdenberg J, Rosser CJ.

BMC Res Notes. 2013 Apr 18;6:156. doi: 10.1186/1756-0500-6-156.

11.

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.

Feldman DR, Einhorn LH, Quinn DI, Loriot Y, Joffe JK, Vaughn DJ, Fl├ęchon A, Hajdenberg J, Halim AB, Zahir H, Motzer RJ.

Invest New Drugs. 2013 Aug;31(4):1016-22. doi: 10.1007/s10637-013-9934-y. Epub 2013 Feb 17.

PMID:
23417696
12.

ACP Journal Club. Review: Self-testing or self-management of oral anticoagulation reduces thromboembolic events and mortality more than usual care.

Hajdenberg J.

Ann Intern Med. 2011 Jul 19;155(2):JC1-6. doi: 10.7326/0003-4819-155-2-201107190-02006. No abstract available.

PMID:
21768572
13.

Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.

Bukowski RM, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Figlin RA.

Oncology. 2010;78(5-6):340-7. doi: 10.1159/000320223. Epub 2010 Aug 20.

PMID:
20733337
14.

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.

Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM; ARCCS Study Investigators.

Cancer. 2010 Mar 1;116(5):1272-80. doi: 10.1002/cncr.24864.

15.

ACP Journal Club. Continuous androgen-deprivation therapy increased risk for diabetes and fragility fractures in older men with prostate cancer.

Hajdenberg J.

Ann Intern Med. 2009 Dec 15;151(12):JC6-14. doi: 10.7326/0003-4819-151-12-200912150-02014. No abstract available.

PMID:
20008750
16.

ACP Journal Club. Adding radiotherapy to endocrine therapy improved survival in locally advanced prostate cancer.

Hajdenberg J.

Ann Intern Med. 2009 Jun 16;150(12):JC6-6. No abstract available.

PMID:
19528551
17.

Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.

Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA.

J Support Oncol. 2006 Oct;4(9):467-71.

PMID:
17080735
18.
19.
20.

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.

Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S; 99-04 Palonosetron Study Group.

Cancer. 2003 Dec 1;98(11):2473-82.

21.

Factor VIII antibodies developing after a spider bite.

Hajdenberg J, Davis J, Araujo RA.

Ann Intern Med. 2000 Apr 18;132(8):677-8. No abstract available.

PMID:
10766694

Supplemental Content

Loading ...
Support Center